Kabir Nath

This article was originally published on PSYCH and appears here with permission. UK-based COMPASS Pathways (NASDAQ: CMPS) recently published data from its Phase IIb trials, with COMP360 psilocybin therapy for treatment-resistant depression. This follows the release of the design for the...